The UK’s National Institute for Health and Care Excellence (NICE) has greenlit the world’s first immunotherapy drug, Teplizumab, which delays the onset of clinical symptoms of type 1 diabetes by an average of up to 3 years. British experts are hailing this decision as the most significant breakthrough in diabetes treatment in over 100 years, since the discovery of insulin.
Type 1 diabetes, which predominantly develops in children and young adults, is an autoimmune condition—where the body’s immune system mistakenly attacks pancreatic cells, causing it to stop producing insulin.
While Teplizumab does not cure the disease, it “reprograms” the immune system to halt the destruction of pancreatic cells. The drug has been approved for adults and children aged 8 and older who have early-stage, asymptomatic (stage 2) type 1 diabetes and are at high risk of developing clinical (stage 3) diabetes. The medication is administered intravenously once daily for approximately 30 minutes over 14 consecutive days, completing the full course of treatment.
Until now, the only available treatment—insulin therapy, discovered 105 years ago—does not alter the course of the disease and merely manages the deficiency. Teplizumab, however, is the first medication to target the underlying cause of the condition, marking a crucial step toward a future where the total prevention of type 1 diabetes becomes possible.
Delaying the onset of diabetes by 3 years grants patients, especially children, invaluable time to reach critical developmental milestones without the burden of constant injections and rigorous glucose monitoring, while giving families precious time to prepare for future management of the condition. The drug will be made available to the National Health Service (NHS) under a confidential discount agreement.
